Johnson & Johnson Ships 4 Million Vaccine Doses, Shots Expected Within 48 Hours

(Justin Tallis / Getty Images #*1229653990)

Daily Caller News Foundation logo
Andrew Trunsky Political Reporter
Font Size:

Johnson & Johnson’s coronavirus vaccine began distribution across the country Monday, and the company’s CEO said shots could begin within 48 hours.

“We’re shipping 4 million [doses] literally as we speak,” Johnson & Johnson CEO Alex Gorsky told NBC News Monday morning. “Within the next 24 to 48 hours, Americans should start receiving shots in arms.”

Gorsky added that the company was on track to distribute 100 million shots by the end of June and 1 billion by the end of 2021. Johnson & Johnson’s vaccine was recommended by the FDA’s vaccine advisory panel on Friday and officially approved one day later. (RELATED: Biden Admin Plans To Distribute 4 Million Johnson & Johnson Vaccine Doses In Under Two Days)

Unlike Pfizer and Moderna’s vaccines, both approved in December, Johnson & Johnson’s is just one dose, meaning that it could effectively alleviate supply shortages reported by multiple states and localities. It can also be stored in normal refrigerators instead of ultra-cold freezers, making it much easier to distribute.

Johnson & Johnson said in January that its vaccine was 72% effective against the virus in the United States, 85% effective against severe virus cases and 100% effective against hospitalization and death. The vaccine, however, was less effective against the coronavirus in South Africa, where a mutated, highly transmissible strain has become dominant. (RELATED: If You Had COVID, One Dose Of The Pfizer Vaccine May Be Enough)

Though the vaccine was only approved for people 18 and older, Gorsky said that Johnson & Johnson is testing its vaccine on children ages 12-18 and pregnant women, with results expected later in 2021.

All content created by the Daily Caller News Foundation, an independent and nonpartisan newswire service, is available without charge to any legitimate news publisher that can provide a large audience. All republished articles must include our logo, our reporter’s byline and their DCNF affiliation. For any questions about our guidelines or partnering with us, please contact